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Obiecsaves . This investigation determined whether attenuation
of the tacltycardia produced lt-~ dobutamine administration would
improve perfusion and function t4 :stal to a severe coronary artery
stenosis.
Rtackgroird. Tachycurdia adversely affects perfusion and func-
tion distal to a coronary artery stenosis . It is not known vhetlter
a specific bradycardic agent can improve blood flow and function
in an isehemic zone during administration of dohutaniine .
Methods . 'file effects of dobutamine (2, 5 and 10 pug/kg body
weight per min) alone and in co bination with zatebraadioe
(0.5 mglkg), a specific bradycardic agent, on hemodyatmde stags,
segment shortening (ultrasound length transducers) and myocar-
dial perfusion (rnicrospheres) were studied in anesthetized dogs
with severe left circumflex coronary a cry stenosis.
Results. A 50% reduction in left circumflex coronary artery
blood flow (58 ± 4 to 29 ± 2 mlhoia [mean value ± SEMI)
produced a decrease in systolic shortening in the ischearde zone .
Only a dose of dobutamine that did not elevate heart rate t2 pglkg
per mice) produced an increase in segment shortening in the
Dobutamine is a positive inotropic agent that acts to stimu-
late beta,-, beta2 - and alpha, -adrenoceptors (l,2) and is
commonly used in patients with left ventricular systolic
dysfunction and concomitant obstructive coronary artery
disease. In the absence of myocardial ischernia, dobutamine
augments cardiac output, myocardial inotropic state and
coronary perfusion, with lesser effects on heart rate and
blood pressure (3,4) . The relative: "°inotropic selectivity" of
dobutamine found at lower doses (1) is lost at higher doses as
the positive chronotropic properties become increasingly
manifest. In the presence of a flow-limiting coronary artery
stenosis, increases in heart rate produced by dobutamine
may serve to further a avate an already compromised
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ischeitaic zone . High doses of dobutamine (it0 pg/kg per
min)
caused an increase in heart rate without improvement in function
and a Deduction in the subead rdiallst picardiol flow ratio
(0.74 ± 0 .06 to 0 . ± 0 .05). Zatebradine administered in the
presence of dobutamine caused a decrease in heart rate, an
increase in sithendocardiallsubepicnrdial blood flow ratio
(0.48 ± 005 to 0.78 ± 0.09) and allowed an increase in ischemic
zone segment shortening, When normalized for changes in heart
rate, ischemic zone subeadocardial flow increased by 123 ± 41 %
`0.39 ± 0.09 to 0 .71 ± 0 .12 ndllt g r beat) . Atrial pacing
abolish the effects of zatebradine .
Conclusions . The present data suggest that the perfusion-
contraction snatching that accompanies a decrease in heart rate
results in enhancement of inotropic stimulation of an ischemie
zone. The actions of zatebradine are related to an increase in
subendocardial blood flow per beat that allows improvement of
regional contractile function,
(J Am Call Cordiol 1994,23 .233-41)
myocardial oxygen supply-demand balance and limit in-
creases in regional contractile function . A decrease in dia-
stolic perfusion time secondary to tachycardia may be espe-
cially deleterious to regional myocardial perfusion and
function distal to a flow-limiting coronary stenosis (5,6) .
Previous studies (7,8) have documented that when inotropic
stimulation with dobutamine is accompanied by an elevation
of heart rate, regional maldistribution of coronary blood flow
may occur . This is reflected in a redistribution of the normal
transmural perfusion gradient, resulting ultimately in no
change or even deterioration of contractile function in the
ischemic zone .
Several compounds, termed specific bradycardic agents,
have been developed that produce a reduction in heart
rate. One such agent, zatebradine (UL-FS 49
; 1,3,4,5-
tetrahydro-7,8-dimethoxy-3-[3-[[2-(3 ,4-dimethoxyphenyl)
ethyl] methylimino]-propyi]-2H-3-benzazepin-2-on-hydro -
chloride), has been shown to
be one of the most efficacious
and selective of these compounds (9) .
Zatebradine has
markedly attenuated exercise-induced increases in
heart rate
in dogs (10,11), with resulting
improvement in perfusion (11)
and function (10,11) in an ischemic zone .
Results of studies
using zatebradine (12-14)
and other specific bradycardic
0735-10971941$6.00
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agents (13) in anesthetized dogs and pigs have also shown
improvement in ischemic zone blood flow and function .
Many (12-14), but not all (11), studies have suggested that
the beneficial effects of zatebradine are solely due to a
reduction in heart rate
. The present investigation was de-
signed to evaluate the effects of dobutamine on hemody-
namic variables, regional myocardial blood flow and regional
contractile function in anesthetized dogs with a severe
coronary artery stenosis and to determine whether the
actions of dobutamine could be favorably altered by selec-
tive attenuation of heart rate through concomitant adminis-
tration of zatebradine .
Methods
Experimental preparation. All experimental procedures
and protocols used in this investigation were rem viewed by the
Animal Care Committee of the Medical College of Wiscon-
sin. All studies conformed to the Guiding Principles in the
Care and Use of Animals of the American Physiological
Society and the Guide for the Care and Use of Laboratory
Animals (DHEW [DHHS] publication no . [NIH] 8523, re-
vised 1985) .
Seven adult mate or female mongrel dogs weighing 18 to
28 kg were fasted overnight, anesthetized with sodium
pentobarbital (25 mg/kg body weight) and sodium barbital
(200 mg/kg) and ventilated by a respirator (Ohio Medical
Products, Airco Inc .) with room air enriched with oxygen .
Respiratory rate and tidal volume were adjusted to maintain
arterial blood gases within normal physiologic limits
(pH 7.35 to 7.45; partial pressure of carbon dioxide, 30 to
35 mm Hg; partial pressure of oxygen, 85 to 100 mm Hg) .
Body temperature was monitored and maintained at 37 .5 t
1°C by a heating pad and servomechanical controller.
Arterial and left ventricular systolic and diastolic pres-
sures were recorded using a 7F dual-pressure transducer-
tipped catheter (SPR-277, Millar) passed through the left
carotid artery into the ascending aorta and left ventricle,
respectively. The peak positive first derivative of left ven-
tricular pressure (dP/dt), an index of global contractility, was
obtained by electronic differentiation of the left ventricular
pressure pulse . A triangular wave of known slope was used
to calibrate the differentiator . A 7F thermodilution pulmo-
nary artery catheter (American Edwards Laboratories) was
advanced into the main pulmonary artery from the jugular
vein . Cardiac output was determined by the thermodilution
technique with the use of a cardiac output computer (series
7000, Marquette Electronics Inc.) and recorded as the aver-
age of three determinations .
The left femoral vein and artery were catheterized for
drug administration and for withdrawal of reference arterial
blood samples used in determination of myocardial tissue
blood flow, respectively . A thoracotomy was performed in
the left fifth intercostal space . The lung was retracted and the
heart suspended in a pericardial cradle . A 1 .0- to 1 .5-cm
segment of the proximal left circumflex coronary artery was
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carefully dissected from the surrounding tissue, and an
electromagnetic flow probe (Statham SP7515, Gould Instru-
ments), was placed around the vessel for measurement of
coronary blood flow . A micrometer-driven mechanical oc-
cluder was positioned distal to the flow probe so that no
branches were present between the probe and the occluder .
The occluder was used to determine zero blood flow and to
produce a noncircumferential stenosis of a constant 3-mm
length. A catheter was placed in the left atriurn for the
injection of radioactive microspheres .
Myocardial segment function (percent systolic shorten-
ing) was measured in the regions perfused by the left anterior
descending and left circumflex coronary arteries by pairs of
piezoelectric crystals . The crystals were inserted (10 to
15 mm apart and 7 to 9 mm deep) into the subendocardium of
the center of the normal (left anterior descending artery) and
ischemic (left circumflex artery) perfusion territories parallel
to fiber orientation . The leads were connected to an ultra-
sound amplifier that transformed the sound pulse into an
electrical signal proportional to the distance between the
crystals . The crystals were precalibrated, and the tracings
were monitored with an oscilloscope (model 2215A, Tek-
tronix Inc .) . Using left ventricular dPldt, end-systolic length
was determined at maximal negative dP/dt, and end-diastolic
length was determined just before the onset of systole . The
lengths were normalized according to the method described
by Theroux et al . (15) . Percent segment shortening was
calculated by the us? of the following equation : Percent
segment shortening = [(End-diastolic length - End-systolic
length)/End diastolic length] x 100. The depth of each
crystal was verified at the completion of each experiment .
The regional distribution of myocardial blood flow was
determined by using the radioactive microsphere technique .
Carbonized plastic microspheres (15-,um diameter) (Dupont)
labeled with cerium-141, chromium-51, niobium-95 or
ruthenium-l03 were obtained as I mCi of nuclide in 5 ml of
isotonic saline solution to which I drop of Tween 80 was
added to minimize aggregation . The mixture was agitated
before injection in a vortex mixer (Cole-Palmer, model 4722)
for 15 min . Approximately 2 to 4 x 106 microspheres were
injected into the left atrium as a bolus followed by a saline
wash. A few seconds before each microsphere injection, a
timed collection of reference flow from the femoral artery
was started (precalibrated Harvard infusion/withdrawal
pump, model 1941, Harvard Apparatus) and maintained at a
constant rate (7 ml/min) for 3 min .
The electrocardiogram, aortic and left ventricular systolic
and diastolic pressures, left ventricular dP/dt, phasic and
mean coronary blood flows and regional segment function in
normal and ischemic zones were continuously recorded on a
polygraph (model 7, Grass Instrument Co .) . Diastolic and
mean coronary vascular resistances were calculated by
dividing diastolic and mean aortic blood pressures by dia-
stolic and mean coronary blood flows, respectively .
The heart was electrically fibrillated and immediately
removed at the conclusion of each experiment . The left
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Table 1. Effects of Dobutamine and Zatebradine Administration on Systemic Ficniodynamic Variables
circumflex coronary artery was then cannufated at the site of
the stenosis, and india ink (5 ml) was injected into the artery
to darken the area of myocardium distal to the stenosis . The
heart was washed with saline solution and fixed in formalin
for 24 h . The left ventricle was separated from the remainder
of the heart and divided into stained and unstained regions .
Multiple tissue samples were obtained from the central zone
of each region . The tissue samples were subdivided into
subepicardial, midmyocardial and subendocardial layers of
approximately equal weight (0 .3 to 0 .6 g). The samples were
weighed and placed in scintillation vials . The activity of each
isotope was determined in duplicate at four energy windows
in a gamma counter (Auto-Gamma 5000 series, Packard
Instrument Co.) . Similarly, the activity of each isotope in the
reference blood samples was also determined . The true
activity of each isotope in the tissue sample was measured
by correcting for energy overlap . Myocardial blood flow (Q.
[mYmin per gD was calculated from the equation Q ., =
Q,-C,,/C,, where Q, = rate of withdrawal (ml/min) of the
reference blood sample ; Cr = true activity (counts/min) of
the reference blood sample ; and C = true activity (counts/
min per g) of the myocardial tissue sample. Myocardial
blood flow values of tissue samples from ischemic and
normal areas were pooled for calculation of flow in the
subepicardium, midmyocardium and subendocardium of
each region .
Experimental protocol . After surgery, the preparation
was allowed to stabilize for 30 min . A stenosis of the left
circumflex coronary artery sufficient to reduce mean coro-
nary blood flow by 50% was produced by the mechanical
occluder . In all experiments, hemodynamic data were mea-
sured before and 15 min after application of the coronary
artery stenosis . Radioactive microspheres were injected
after a stable level of stenosis had been achieved . Hemody-
namic changes were measured during three doses of dobu-
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*p < 0.05 versus post-stenosis
values . tp < 0.05 versus dobutarnine (10 jig/kg per min) . Values presented are mean value ± SEMI
. LVEDF - left ventricular
end-diastolic pressure : LVSP = left ventricular systolic pressure : MAP = mean arterial pressure, +dPidt = peak positive first derivative of left ventricular
pressure ; rate-pressure product = product of heart rate x left ventricular systolic pressure
; SVR = systemic vascular resistance-, wr = weight .
famine (2, 5 and 10 pgAg per min) . Each infusion rate was
allowed to reach steady state conditions for a period of
15 min, Microspheres were injected during the high dose for
measurement of myocardial blood flow . Intravenous zate-
bradine (0.5 mg/kg, intravenously) was administered during
the high dose of dobutamine, and hemodynamic data, seg-
ment function and myocardial perfusion were again mea-
sured . Heart rate was then increased to the revel present
before zatebradine administration by means of atrial pacing,
and the final measurement of tissue flow was obtained . In all
experiments, at least 15 min was allowed after drug admin-
istration or atrial pacing before data collection to ensure a
stable hemodynamic state .
Drugs. Dobutamine and zatebradine were dissolved in
0.9% saline solution and freshly prepared on the day of each
experiment .
Statistical analysis. The transmural distribution of coro-
nary blood flow (subendocardial/subepicardial blood flow
ratio) is expressed as the ratio of flow per gram of sub-
endocardiurn to flow per gram of subepicardium . Unless
otherwise specified, statistical analysis of results was carried
out by analysis of variance with repeated measures, and
when a significant overall effect was detected, the Bonfer-
roni modification of the t test was applied to compare single
mean values . The Student paired t test was utilized to
compare post-stenosis control flows in the normal and isch-
emic zones. Differences were considered significant at p <
0.05. All results are presented as mean value ± SEW
Results
Hemodynamic actions of dobu`amine and zatebradine .
Systemic hemodynamic data are summariz,.d it Table 1
.
Stenosis of the left circumflex coronary artery produced no
changes in systemic hemodynamic status
. Administration of
Post-stenosk
Dobutamine
Zatebradine
10 .5 mg/kg body wt)
+ Dobutamine
(10
fag/kg
per min)
Zatebradine
(n_5 mg/kg body wt)
+ Pacing
+ Dobutamine
2 pg!kg
per min
5 1pg"4
per min
10 g&g
per minPrestenosis (10 µg/kg per min)
Heart rate (beats.' min) 125 t 2 125 ± 2 130 ± 2 l52 = 4* 166 = 51 97 ± 1 11 !66 ± 54
MAP (mm Hg) 100 ± 5 100 ± 5 Ill ± 6 119 ± 7* 120 ± 6* 105 ± 5t 119 ± 5*
LVSP Imm Hg) 115 ± 5 120 ± 5 129 ± 6 140 ± 7* 140 ± 7* 136 ± 8* 138 ± 5*
LVEDP (min Hg) 6 ± 1 7 ± 1 6 ± I 6+1 631 731 631
Rate-pressure product
(mrn Hg-beatimin-10 1)
14 .4 ± Of 15 .0 t 0 .9 16 .9 ± 0 .9 21 .2 31 .1 23 .1 1T 12 .8 :7 ON 22.9 ot 1s*
2,271 ± 28*+dPIdt (mitt Hg/s) 1 .729 ± 107 1,768 ± Ill 2,118 ± 46-" 2,261 ± 24* 2,275 :t 37* 2,220 ± 23*
Cardiac output
(titers/min P
3 .0 t 0 .2 3 .0 t 0 .2 3 .8 ± 0 .4 4.410.5* 4.930.6* 31 ± 14t 4.930.6*
Stroke volume (milbeat) 24 ± 1 24 ± 1 29 ± 3 29=3 3033 40 5*t 29±3
SVR (dynes-s . cm -5 ) 2,715 ± 163 2,910 ± 177 2,485 ± 251* 2,280 ± 236* 2,080 ± 1,220* 2,290 240* 2,190 ± 230*
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Tare 2
. Effects of Dobutamine and Zatebradine on Coronary Hemodynamic Variables
*
P
< 0.05 versus post-stenosis
value . Values presented are mean value ± SUM. ru = resistance units
; wt = weight .
dobutamine caused dose-related increases in heart rate, left
ventricular systolic pressure, rate-pressure product, left
ventricular peak positive V/dt and cardiac output . Admin-
istration of zatebradine during the high dose of dobutamine
produced a significant reduction in heart rate . The decrease
in heart rate was accompanied by a reduction in mean
arterial pressure. Left ventricular systolic pressure and peak
positive dP/dt were unchanged by zatebradine . Cardiac
output was reduced by zatebradine compared with the high
dose of dobutamine, but stroke volume was significantly
increased. Atrial pacing to the heart rate present before
zatebradine administration abolished these hemodynamic
changes. The effects of dobutamine and zatebradine on
coronary hemodynamic variables are presented in Table 2 .
Application of a severe stenosis to the left circumflex coro-
nary artery produced a reduction in blood flow of approxi-
mately 50% . Administration of dobutamine or zatebradine,
or both, caused no change in diastolic or mean coronary
blood flow or coronary vascular resistance .
Effects ofdobufamba aW zatebradine on regional myocar-
dial fuactW. Changes in systolic shortening in the normal
and ischemic zones are depicted in Figures l and 2, respec-
tively. Hemodynamic variables and segment length recorded
in a typical dog during dobutamine administration in the
absence or presence of zatebradine are shown in Figure 3 .
Contractile function of the normal zone was increased by
dobutamine in a dose-related fashion . Administration of
zatebradine or atrial pacing had no effect on segment short-
ening of the normal zone. A significant reduction in function
of the ischemic zone occurred coincident with application of
the stenosis . Administration of low doses of dobutamine
(2 pg/kg per min) produced significant improvement in
ischemic zone function
. Higher doses of dobutamine, how-
ever, produced no change in ischemic zone function
. Ad-
ministration of zatebradine was associated with an increase
in segment shortening in the ischemic zone . The improve-
ment in function was abolished by atrial pacing to rates
present before zatebradine administration
.
Effects of dobutsmine and zatebradine an myocardial bl
flow. Alterations in regional myocardial blood flow are
summarized in Table 3. Blood flow to the normal zone was
increased by dobutamine . Zatebradine decreased blood flow
slightly, and atrial pacing restored blood flow to levels
comparable to those present during the high dose of dobu-
tamine. No change in the subendocandiallsubopicMal
blood flow ratio was produced by dobutamine, zatebradine
or atria] pacing in the normal zone (Fig . 4) .
B" flow to all layers of the ischemic zone (subepicar-
dial, midmyocardial and subendocardial), including suben-
docardial flow per beat, was significantly (p < 0 .05) reduced
by the stenosis compared with flow in the normal zone .
Subepicardial blood flow in the ischemic zone was signifi-
Figure 1 . Segment shortening data in the normal (left anterior
descending coronary artery) zone before (PRE) left circumflex
coronary artery stenosis ; after (POST) stenosis ; and after adminis-
tratirm of dobutamine 1) alone, 2) simultaneously with zatebradine
(UL-FS 49), and 3) simultaneously with zatebradine and atrial
pacing. *p < 0.05 versus post-stenosis v alues . tp < 0.05 versus
dobutamine atone (10
#g/kg
body weight per min) .
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RAMMING
Presicnosis Post-stenosis
Dubutaraine
WAKhe
(0.5 mgfkg body wt)
+ Dobularnine
110 pWkg per min)
Zatebradine
10.5 mgikg body wt)
+ Facing
+ Debutamine
(10 paggt'kp, per mina
2 pgfkg
per min
5 mog
per ratio
10 AgAg
per min
Diastolic coronary blood
flow (MI/min)
84 ±- 4 4 49 :t 4 42 ± 4 44±5 40±5 40±5 39- 4
Mean coronary blood
flow (mUmin)
58 t 41 29
r
2 30 ± 2 31±3 29t3 29±3 29±3
Diastolic coronary
vascular resistance ' vu)
1 .I ± 0.1= 2 .4 ± 13 2 .6 ± &3 2.7±0.4 2.9±0.3 2 .4 ± 12 3.0±0.2
Mean coronary vascular
resistance (ru)
1 .8 ± TP 3 .8 ± 0 .9 3 .9 ± 0 .4 4A 4
.0±05 4.2#0.4 3 .8±0.4 4.3±0.4
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Figure 2. Segment shortening data ire the ischemic zone before left
circumflex coronary artery stenosis ; after stenosis, and after admin .
istaafion of dobutarnine 1) alone, 2) simultaneously with zatebm-
dine, and 3) simultaneously with zatebradine and atria[ pacing .
Abbreviations and symbois as in F--g-ure in
cantly increased by dobutaraiine without alteration of mid-
myocardial or subendocardial blood flow . Thus, the suben-
docardial/subepicardial flow ratio was significantly reduced
by dobutamine (Fig . 5). Zatebradine returned the ischemic
zone transmural blood flow ratio to values present before
dobutamine infusion . The erect of zatebradine on the trans-
mural distribution of coronary flow was abolished by atrial
pacing (Fig . 5) .
Discussion
The findings from this investigation demonstrate that the
positive inotropic actions of dobutamine in ischemicc myc-
Figure 3. Typical recording of coronary blood flow
(CBF), aortic pressure (AP), first derivative of left
ventricular pressure (dpldt) . left ventricular systolic
pressure (LVSP) and segment length (SL) before and
after coronary artery stenosis and after administration
of dobutamine alone and simultaneously with zatebra-
dine (UL-FS 49). All traces were recorded at the same
paper speed (50 mm/s) . Other abbreviations as in
Figure 1 .
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cardium can be dcc by the concomitant administration
of zatebradine, a specific brad , ycardic agcnt . The results also
show the adverse effects of dobutamine-induced increases in
heart rate on regional myocardial perfusion and segment
function and the improvement in perfusion and function
attainable when the positive chronotropic properties of this
agent are eliminated . The improvement in isehemic zone
perfusion and function produced by zatebradine were elim-
inated by atrial pacing, suggesting that the beneficial effects
of zatebradine were due solely to a reduction
in heart fate .
A new class of anti-ischemic drugs termed specific brady-
cardic agents have been developed that produce dose-related
reductions in the rate of sinus node discharge (9,16) . One
such agent is a substituted benzothiopheae, structurally
related to verapamil, known as zatebradine . This compound
reduces heart rate without direct alterations in inotropic or
lusitropic state or vascular tone (9,12,13,16,17) . Previous
investigations in conscious dogs have demonstrated that
zatebradine improves perfusion and function in a collateral-
dependent zone during exercise (11) . Similar improvements
in ischemic zone perfusion and function produced by zate-
bradine have also been found in experimental models using
anesthetized dogs (12) and pigs (14) .
hsotropic stimulation 9F ischemle myocardium . In the
present investigation, dobutamine administration produced
dose-related increases in heart rate, mean arterial pressure,
rate-pressure product, left ventricular peak positive dPldt
and cardiac output and a decrease in systemic vascular
resistance. Similar hemodynamic changes caused by dobu-
tamine have been found in previous studies using anesthe-
tized dogs (18,19). In the present and previous (8,20,21)
investigations, dobutamine produced progressive increases
in percent segment shortening in nonischemic regions, ac-
companied by uniform increases in blood flow to the sub-
100
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1 S®C
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0
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E -2000
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Table 3
. Effects of Dobutamine and Zatebradine Administration on Regional Myocardial Perfusion
W
'U
l
I
1 .3
1 .1
0 .9
0.7
0.5
*p < 0.05 versus post-stenosis v alues. t p < 0.05 versus dobutamine (10 µg/kg per min) . Values presented are mean value ± SEM . wt = weight .
endocardium and subepicardium. Regional function and perfu-
sion in the normal region were unaffected by zatebradine .
A stenosis sufficient to reduce rest coronary blood flow
by 50% (as assessed by the electromagnetic flow probe) was
used in our study . This degree of stenosis resulted in a
decrease in subendocardial blood flow compared with that in
the normal region, with a concomitant depression of con-
tractile function . Only doses (2 Ag/kg per min) of dobutamine
that produced no change in heart rate increased shortening in
the ischemic zone in the absence of zatebradine . Higher
doses of dobutamine were accompanied by increases in
heart rate but no change in ischemic zone segment shorten-
Figure 4. Normal zone (left anterior descending coronary artery)
subendocardiaUsubepicardial blood flow ratio (ENDO/EPI) after left
circumflex coronary artery stenosis application and after adminis-
tration of dobutamine 1) alone, 2) simultaneously with zatebradine
(UL-FS 49), and 3) simultaneously with zatebradine and atriai
pacing .
PCT
10 10
STENOSIS
DOBUTAMINE (pWWmq
	
I
SD
0 .50
F~ --UL-FS 49
(mg/kg)--1
PACING
ing. Comparison with previous experimental studies inves-
tigating the effect of dobutamine on ischemic zone function
is difficult because of differences in the severity of coronary
stenoses utilized and the different doses of dobutamine
applied .
In anesthetized dogs with total coronary artery occlusion .
dobutamine in doses larger (20 jiglkg per min) than those
used in the present study increased ischernic zone blood flow
(21) . However, this same dose produced an increase in ST
segment elevation and may have increased the extent of
ischemic myocardial injury (21) . Vatner and Haig (20) dem-
onstrated in anesthetized dogs with complete coronary oc-
Figure 5. Ischemic zone subendocardiallsubepicardial blood flow
ratio after left circumflex coronary artery stenosis application and
after administration of dobutamine 1) alone, 2) simultaneously with
zatebradine (UL-FS 49), and 3) simultaneously with zatebradine and
atrial pacing . Abbreviations and symbols as in Figures I and 4 .
LU
ZW
1 .3
7A
01
0.7
0.5
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JK~"nll
POST ~
a0 10
1
SrEENCOGS	 DOBUTRUME (KAWW)	
0,50
0 .50
_IUM 49 (Yog)
+
PACING
Post-stenosis
Dobutamine
9!0 gekg bedy Wt per min)
Dobutamine
(10 ;tglkg body wt per min)
+ Zatebn. dine
(0 .5 mgikg body wt)
Dobutarmne
(10 pg/kg body wt per min)
+ Zatebradine
(0.5 mglkg body wt) +
Pacing
Normal zone (ml/min per g)
Subepicardium 1 .26 -± 0.22 2.07 ± 0 .25*
1 .79 t 0.25* 1 .95 ± 0 .20*
Midmyocardium 1 .07 t 0.19 1 .69 = 0 .29* 1 .55 0.20* IAI 0 .26'
Subendocardium 1 .02 t 0 .12 1 .55 ± 0 .14 1: 1 .62 117' 1 .57 0 .20*
Transmural 1 .11 :t: 0 .17 1 .77 = 0.21" 1 .65 0. 19* 1.71±0.21*
Subendocardial flow per beat 0 .82 0 .10 0.95 t 0 .09 LO W, 095 oil
(int/100 g per beat)
Ischemic zone (ml/min per g)
Subepicardium 0.81 2 0.09 1 .27 ± 0.17* 0.87± allt 1 .08 ±0.19
Midmyocardium 0.68 0.09 0.75 ± 0.14 .722112 160 109
Subendocardium 0.60 0.07 0.69 ± 0.14 0.68}012 0.52±0.08
Transmural 0.70 0.08 0.89 ± 0.14 .76}011 0.7 3±0.11
Subendocardial flow per beat 0.48 0.06 0.39 ± 0.09 0 .71 ± 0.12*t 0.32±0.05
(ml/l00 g per beat)
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elusion that myocardial perfusion in the ischemic zone was
unchanged by dobutamine, provided that heart rate was
unchanged. Tissue flow, subendocardial/subepicardial Row
ratio and regional myocardial function were depressed if
tachycardia was produced . In the present study, utilizing a
severe coronary stenosis but with persistent anterograde
flow, dobutamine (10 pglkg per min) increased only subepi-
cardial flow, whereas midmyocardiai and subendocardial
perfusion remained unchanged in the ischemic zone . Re-
gional function was not improved at doses that produced
increases in heart rate . Similar results were found by
eGillern et al . (19) . Dobutamitae (10 p,_a/kg per rain) failed to
improve ischemic ?one segment shortening in anesthetized
dogs with a coronary stenosis sufficient to produce a >4 e
reduction of reactive hyperemia .
A relative or absolute decrease in subendocardial blood
flow with an associated reduction in the subendocardial!
subepicardial blood flow ratio has been demonstrated not
only with dobutamine (8,18), but also with dopamine, iso-
proterenol and norepinephrine (4,22) after exercise (11) a7nd
during atrial pacing (6) . Auloregulatory mechanisms pre-
serve approximate equality of flows per gram across the
ventricular wall as coronary perfusion pressure changes .
However, these autoregulatory mechanisms may fail, and
subendocardial ischemia may ensue when pressure distal to
a coronary stenosis decreases below --70 mm fig (23) .
Dobutamine (10 jig/kg pcr nun) has previously been shown
to reduce perfusion pressure distal to a coronary stenosis
and to decrease the subendocardiallsubepicardial blood flow
ratio (8) . Tachycardia (24) and exercise (25) may produce an
adverse shift in the lower limit of subendocardial autorege-
lation, as manifested by the onset of subendocardial isch-
emia at a higher distal coronary artery pressure . In the
present study, although higher doses of dobutamine did not
cause regional function to deteriorate below control (post-
stenosis) levels, the failure of regional wall function to
improve was secondary to persistence of a subendocardial
perfusion deficit .
Control of heart rate during isotropic stimulation . After
zatebradine administration, contractile function of the isch-
emic segment was improved dramatically by dobutamine .
Zatebradine produced a decrease in heart rate without
change in left ventricular peak positive dP/dt or function of
the control region . The decrease in heart rate produced by
zatebradine during the infusion of dobutamine was associ-
ated with a marked increase in function of the ischemic zone .
Potential reasons for the improvement in regional contractile
function relate to a favorable alteration in myocardial oxy-
gen supply-demand balance . Previous investigations
have
shown that beta-adrenergic blocking agents, the non-beta-
blocker N-dimethyl propranolol, as well as the specific
bradycardic agents alinidine, AQ-AH 208 and zatebradine,
favorably redistribute ischemic zone flow to the subendocar-
dium (12,13,26,27) . Mechanisms
by which this redistribution
of flow could occur include an increase in diastolic perfusion
time; restoration of autoregulation, particularly
in the
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subepicardium of
tlhe ischemic zone ; and direct effects on
collateral blood flow,
Regional myteaedial blood flow . The majority of myocar-
dial blood flow occurs during diastole, and subendocardial
blood flow and perfusion distal to a coronary obstruction are
almost cxcluse.'e1 ' diastolic (28) . As a consequence, should
diastolic perfusion time be reduced, the subendocardium will
receive the least flow (28) . Interventions that prolong dias-
tole will proportionately increase perfusion to the suben-
docardium (5) . It is well documented that regional myocar-
dial function is closely related to the level of subendocardial
blood flow . A linear relation exists between the level of inner
wall perfusion and regional wall function (29). This relation
has been termed perfusion-contraction matching, whereby
regional function is dependent on and matched to subendo-
cardial blood flow under steady state conditions (14,30) .
indolft et al . (14) normalized subendocardial blood flow for
heart rate (subendocardial blood flow per beat) and de-
scribed a good correlation between perfusion and regional
contractile function .
In the present study, zatebradine caused no change in
subendocardial now in the ischemic region, but percent
segment shortening dramatically improved . When normal-
ized for heart rate, however, subendocardial blood flow per
beat was significantly increased by zatebradine . Further-
more, the failure of segment shortening to be increased by
high doses of dobutamine before zatebradine administration
corresponded with an unchanged normalized subendocardial
blood now . Expressing myocardial perfusion in this manner
may account for changes in both myocardial oxygen supply
and demand . This emphasizes that the functional response to
bradycardia in an ischemic zone may result from modifica-
tion of both oxygen demand (fewer contractions per minute)
and a substantial increase in subendocardial blood flow per
beat (increased oxygen availability), thus allowing aug-
mented regional contraction . In the present investigation,
regional myocardial oxygen consumption was not directly
measured . it is generally held that bradycardia will decrease
myocardial oxygen consumption, but this may not apply
equally to the subepicardium and subendocardium . Reduced
contractions per minute would decrease myocardial oxygen
consumption, but improvement in contractile function dur-
ing bradycardia would be expected to increase oxygen
consumption per beat . Prediction of the effects of bradycar-
dia on
ischemic myocardial oxygen consumption is complex,
and until practical methods for measuring regional oxygen
consumption become available, the relative contributions of
bradycardia-induced changes in myocardial oxygen demand
and supply toward improved regional contractile perfor-
mance remain speculative .
As diastolic perfusion time decreases, a selective de-
crease in subendocardial vascular resistance occurs to main-
tain uniform net transmural perfusion through autoregulation
(31)
. This compensatory mechanism may fail in the presence
of a coronary artery obstruction . A decrease in diastolic
perfusion time or distal coronary perfusion pressure, or
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both, may exhaust vasodilator reserve in the subendocar-
dium, with a resultant "vertical steal" (an increase in
subepicardial perfusion at the expense of the subendocar-
dium)
. Several beta-blocking agents have been shown to
increase distal perfusion pressure and to reduce the calcu-
lated resistance of a coronary stenosis (26,27,32) . A reduc-
tion in myocardial oxygen demand by beta-blockers may
restore the ability of the subepicardial vasculature to auto-
regulate, thus diverting flow to the more intensely ischemic
subendocardium. In the present investigation, zatebradine
caused a decrease in subepicardial flow of the ischemic zone
and an increase in the subendocardiallsubepicardiaal blood
flow ratio. Distal coronary artery perfusion pressure was
unmeasured. However, the dominant factor causing im-
provement in regional function in the present and previous
(14) studies was the prolonged diastolic perfusion time,
which increased subendocardial flow per beat . Left ventric-
ular end-diastolic pressure remained unchanged throughout
the course of these experiments . Previous studies in anes-
thetized dogs with a significant coronary artery stenosis have
also demonstrated that left ventricular end-diastolic pressure
remains unaltered after dobutamine infusion (8,19) . Al-
though increased diastolic filling as a consequence of dia-
stolic prolongation would be expected, an increase in left
ventricular end-diastolic pressure was not observed after
zatebradine .
The present investigation was performed in barbiturate-
anesthetized dogs, resulting in an elevated heart rate (125
beats/min) in the control state . In the absence of a subse-
quent positive chronotropic stimulus (e .g., dobutamine),
baseline tachycardia itself would be expected to enhance the
beneficial actions of zatebradine compared with drug admin-
istration during lower heart rates . Had the control heart rate
been lower, it is possible that the peak heart rates achieved
with dobutamine would have been less, thereby reducing the
subsequent beneficial effect of zatebradine. Additionally,
with slower control heart rates, post-stenosis ischemic zone
segment shortening might be a greater percent of prestenosis
control values . This would tend to reduce the percent
improvement that could be produced by zatebradine .
Conclusions. The results of this investigation demon-
strate that the perfusion-contraction matching that accom-
panies the decrease in heart rate produced E y zatebradine
administration allows improved post-stenotic myocardial
function during inotropic stimulation despite a persistent
reduction in subendocardial blood flow. The improvement in
regional function is entirely abolished by atrial pacing. These
findings underscore the detrimental effect of tachycardia on
post-stenotic myocardial function . The actions of zatebra-
dine are likely to be due solely to a reduction in heart rate,
leading to fewer active contractions per unit time (decreased
oxygen consumption) and a substantial increase in subendo-
cardial blood flow per beat (increased oxygen availability),
thus allowing augmented regional contraction .
Clinical implications . Specific bradycardic agents such as
zatebradine represent a unique therapeutic modality for the
JACC Vol. 23, No . I
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treatment of cardiovascular disease . Zatebradine markedly
reduces heart rate without depressing myocardial contractil-
ity, unmasking alpha-adrenergic vasoconstrictor mecha-
nisms in the coronary vasculature or directly affecting vaso-
motor tone in the periphery . Thus, in select clinical
circumstances, zatebradine may have important advantages
over agents such as beta-adrenergic receptor antagonists or
slow calcium channel blocking agents. The ability to aug-
ment subendocardial blood flow per beat and regional func-
tion in an ischemie zone during administration of dobu-
tamine is of distinct clinical interest . When inotropic support
is required for patients with coronary artery disease, the
addition of a specific bradycardic agent may reduce the
extent of ischemia caused by positive chronotropic stimula-
tion or allow higher doses of these agents to be used, or both .
We extend our appreciation to John Tessmer, BS, Doug Hettrick, MS and
Dave Schwabe, BS for excellent technical assistance and to Mimi Mick, BA
and Angela Barnes, BA for preparation of the manuscript .
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